
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening and updating guidelines on the testing of products.






